The bigger they are, the harder they fall - and the more notable their absence. First Data raised $2.6 billion in the year's largest IPO, but broke issue on the first day. Two small biotechs priced IPOs that were 1/100th the size of First Data's offering....read more
Cerecor, which is developing a novel adjunct therapy for major depressive disorder, raised $26 million by offering 4.0 million shares at $6.50, within the range of $6 to $7. In its prior amendment, Cerecor had disclosed that it would be offering 4.23...read more
As many as 11 companies could go public this week, including the year's largest IPO (Digicel) and the fastest-growing company (Pure Storage). Both have proposed market caps of more than $3.5 billion, while six others target valuations of $300 million or...read more
Home, home below the range: all five deals this week priced below the range. There were eleven companies on the IPO calendar this week, but only five were ...read more
US IPO Weekly Recap: Year's largest IPO First Data raises $2.6 billion and falls flat
The bigger they are, the harder they fall - and the more notable their absence. First Data raised $2.6 billion in the year's largest IPO, but broke issue on the first day. Two small biotechs priced IPOs that were 1/100th the size of First Data's offering....read more
Depression biotech Cerecor prices downsized IPO at $6.50, within the range
Cerecor, which is developing a novel adjunct therapy for major depressive disorder, raised $26 million by offering 4.0 million shares at $6.50, within the range of $6 to $7. In its prior amendment, Cerecor had disclosed that it would be offering 4.23...read more
Week ahead: Fourth quarter kicks off with 11 IPOs set for the week of October 5
As many as 11 companies could go public this week, including the year's largest IPO (Digicel) and the fastest-growing company (Pure Storage). Both have proposed market caps of more than $3.5 billion, while six others target valuations of $300 million or...read more
US IPO Weekly Recap: Only five deals get done after massive valuation cuts
Home, home below the range: all five deals this week priced below the range. There were eleven companies on the IPO calendar this week, but only five were ...read more